Literature DB >> 22288591

The European internet-based patient and research database for primary immunodeficiencies: update 2011.

B Gathmann1, N Binder, S Ehl, G Kindle.   

Abstract

In order to build a common data pool and estimate the disease burden of primary immunodeficiencies (PID) in Europe, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Since its start in 2004, 13,708 patients from 41 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity with 2880 patients or 21% of all entries, followed by selective immunoglobulin A (sIgA) deficiency (1424 patients, 10·4%). The total documented prevalence of PID is highest in France, with five patients per 100,000 inhabitants. The highest documented prevalence for a single disease is 1·3 per 100,000 inhabitants for sIgA deficiency in Hungary. The highest reported incidence of PID per 100,000 live births was 16·2 for the period 1999-2002 in France. The highest reported incidence rate for a single disease was 6·7 for sIgA deficiency in Spain for the period 1999-2002. The genetic cause was known in 36·2% of all registered patients. Consanguinity was reported in 8·8%, and 18·5% of patients were reported to be familial cases; 27·9% of patients were diagnosed after the age of 16. We did not observe a significant decrease in the diagnostic delay for most diseases between 1987 and 2010. The most frequently reported long-term medication is immunoglobulin replacement.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288591      PMCID: PMC3374280          DOI: 10.1111/j.1365-2249.2011.04542.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

Review 1.  Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID).

Authors:  L Hammarström; I Vorechovsky; D Webster
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  The European internet-based patient and research database for primary immunodeficiencies: results 2004-06.

Authors:  A-M Eades-Perner; B Gathmann; V Knerr; D Guzman; D Veit; G Kindle; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Authors:  J M Boyle; R H Buckley
Journal:  J Clin Immunol       Date:  2007-06-19       Impact factor: 8.317

4.  A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.

Authors:  Bénédicte Neven; Aude Magerus-Chatinet; Benoit Florkin; Delphine Gobert; Olivier Lambotte; Lien De Somer; Nina Lanzarotti; Marie-Claude Stolzenberg; Brigitte Bader-Meunier; Nathalie Aladjidi; Christophe Chantrain; Yves Bertrand; Eric Jeziorski; Guy Leverger; Gérard Michel; Felipe Suarez; Eric Oksenhendler; Olivier Hermine; Stéphane Blanche; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

5.  The ESID Online Database network.

Authors:  D Guzman; D Veit; V Knerr; G Kindle; B Gathmann; A M Eades-Perner; B Grimbacher
Journal:  Bioinformatics       Date:  2007-01-19       Impact factor: 6.937

6.  Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee.

Authors:  Raif S Geha; Luigi D Notarangelo; Jean-Laurent Casanova; Helen Chapel; Mary Ellen Conley; Alain Fischer; Lennart Hammarström; Shigeaki Nonoyama; Hans D Ochs; Jennifer M Puck; Chaim Roifman; Reinhard Seger; Josiah Wedgwood
Journal:  J Allergy Clin Immunol       Date:  2007-10       Impact factor: 10.793

7.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.

Authors:  Philip S Rosenberg; Blanche P Alter; Audrey A Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Carol Fier; Melvin Freedman; George Kannourakis; Sally Kinsey; Beate Schwinzer; Connie Zeidler; Karl Welte; David C Dale
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

8.  Primary immunodeficiency diseases in Australia and New Zealand.

Authors:  Philippa Kirkpatrick; Sean Riminton
Journal:  J Clin Immunol       Date:  2007-06-22       Impact factor: 8.317

9.  Statistics review 10: further nonparametric methods.

Authors:  Viv Bewick; Liz Cheek; Jonathan Ball
Journal:  Crit Care       Date:  2004-04-16       Impact factor: 9.097

10.  Primary immunodeficiency disorders in Kuwait: first report from Kuwait National Primary Immunodeficiency Registry (2004--2006).

Authors:  Waleed Al-Herz
Journal:  J Clin Immunol       Date:  2007-11-16       Impact factor: 8.317

View more
  36 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

2.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

3.  Collaborating to improve quality of life in primary immunodeficiencies: World PI Week, 2013.

Authors:  Ricardo Sorensen; Amos Etzioni; Ahmed Aziz Bousfiha; John B Zeiger
Journal:  J Clin Immunol       Date:  2013-07-11       Impact factor: 8.317

Review 4.  Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland.

Authors:  Małgorzata Pac; Ewa Bernatowska
Journal:  Eur J Pediatr       Date:  2016-06-29       Impact factor: 3.183

5.  Primary immunodeficiency diseases: a 30-year patient registry from the referral center for primary immunodeficiencies in Greece.

Authors:  Athanasios Michos; Maria Raptaki; Sofia Tantou; Marianna Tzanoudaki; Kleopatra Spanou; Manolis Liatsis; Nikki Constantinidou; Evangelia Paschali; Ioanna Varela; Olga Moraloglou; Chryssa Bakoula; Maria Kanariou
Journal:  J Clin Immunol       Date:  2014-07-01       Impact factor: 8.317

6.  Broadening the translational immunology landscape.

Authors:  M Peakman
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

7.  The PedPAD study: boys predominate in the hypogammaglobulinaemia registry of the ESID online database.

Authors:  E J H Schatorjé; B Gathmann; R W N M van Hout; E de Vries
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  Primary Immunodeficiency Diseases in Saudi Arabia: a Tertiary Care Hospital Experience over a Period of Three Years (2010-2013).

Authors:  Bandar Al-Saud; Hamoud Al-Mousa; Sulaiman Al Gazlan; Abdulaziz Al-Ghonaium; Rand Arnaout; Amal Al-Seraihy; Sahar Elshorbagi; Nazeema Elsayed; Jawad Afzal; Hasan Al-Dhekri; Saleh Al-Muhsen
Journal:  J Clin Immunol       Date:  2015-09-22       Impact factor: 8.317

9.  Molecular defects in Moroccan patients with ataxia-telangiectasia.

Authors:  L Jeddane; F Ailal; C Dubois-d'Enghien; O Abidi; I Benhsaien; A Kili; S Chaouki; Y Kriouile; N El Hafidi; H Fadil; R Abilkassem; N Rada; A A Bousfiha; A Barakat; D Stoppa-Lyonnet; H Bellaoui
Journal:  Neuromolecular Med       Date:  2013-01-16       Impact factor: 3.843

10.  Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.

Authors:  M Ponsford; E Carne; C Kingdon; C Joyce; C Price; C Williams; T El-Shanawany; P Williams; S Jolles
Journal:  Clin Exp Immunol       Date:  2015-09-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.